Interv Akut Kardiol. 2011;10(4):176-181

Thrombembolic and bleeding complications in heart valve prosthesis holders

Jaroslav Dušek1, Miroslav Brtko2, Josef Šťásek1, Josef Bis1, Jan Vojáček1, Pavel Polanský2, Dušan Černohorský3
1 I. interní klinika, Fakultní nemocnice Hradec Králové, Univerzita Karlova Praha, Lékařská fakulta Hradec Králové
2 Kardiochirurgická klinika, Fakultní nemocnice Hradec Králové,
Univerzita Karlova Praha, Lékařská fakulta Hradec Králové
3 Gerontometabolická klinika, Fakultní nemocnice Hradec Králové,
Univerzita Karlova Praha, Lékařská fakulta Hradec Králové

Many complications may occur in patients with heart valve replacement. The thrombembolic and bleeding complications are the

most considerable. Choosing between the mechanic and biological valve prosthesis is very important due to many reasons. In case

of mechanical valve prosthesis we can expect life long good function of the prosthesis at the expense of higher thrombembolic and

bleeding complications. The incidence of mechanical valve prosthesis thrombosis is in the range 0.2–1.8 %/patient/year. The treatment

depends on patient´s condition and presence of valve prosthesis obstruction. Reoperation, thrombolysis or anticoagulation therapy is

considered. The bleeding complications are related to the need of life long anticoagulation therapy for patients with mechanical valve

prosthesis. Its frequency is related to the intensity and stability of the anticoagulation therapy, to many factors on the patient´s site and

drug interactions of the warfarin.

Keywords: valve disease, thrombembolic complication, bleeding complication

Published: July 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dušek J, Brtko M, Šťásek J, Bis J, Vojáček J, Polanský P, Černohorský D. Thrombembolic and bleeding complications in heart valve prosthesis holders. Interv Akut Kardiol. 2011;10(4):176-181.
Download citation

References

  1. Di Marco F, Meneghetti G, Gerosa G. Early anticoagulation after aortic valve replacement with bioprosthesis: Time to abandon it? J Thorac Cardiovasc Surg 2005; 130: 1482-1483. Go to original source... Go to PubMed...
  2. El-Husseiny M, Salhiyyah K, Raja SG, et al. Should warfarin be routinely prescribed for the first months after a bioprosthetic valve replacement? Interact Cardiovasc Thorac Surg 2006; 5: 616-623. Go to original source... Go to PubMed...
  3. Dominik J, Žáček P. Chirurgická léčba chlopenních vad. In: Vojáček J, Kettner J. Klinická kardiologie. PA: Nucleus HK, 2009: 518-533.
  4. Gherli T, Colii A, Fragnito C, et al. Comparing warfarin with aspirin after biological aortic valve replacement. A prospective study. Circulation 2004; 110: 496-500. Go to original source... Go to PubMed...
  5. Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann J. Antithrombotic and thrombolytic therapy. 8th ed. ACCP Guidelines. Chest 2008; 6: 67S-968S. Go to original source...
  6. Popelová J, Benešová M, Brtko M, et al. Doporučené postupy České kardiologické společnosti pro diagnostiku a léčbu chlopenních srdečních vad v dospělosti. Cor Vasa 2007; 49: 6-45.
  7. Brtko M, Dominik J. Pacient po operaci chlopenní vady. In: Vojáček J, Kettner J. Klinická kardiologie. PA: Nucleus HK, 2009: 534-541.
  8. Licata A, Matthai WH. Evaluating the etiology of mechanical valve obstruction: use clinical parameters, fluoroscopy, and echocardiography. Cathet Cardiovasc Intervent 2002; 55: 495-500. Go to original source... Go to PubMed...
  9. Lin SS, Tiong IYH, Asher CR, Murphy MT, Thomas JD, Griffin BP. Prediction of thrombus-related mechanical prosthetic valve dysfunction using transesophageal echocardiography. Am J Cardiol 2000; 86: 1097-1101. Go to original source... Go to PubMed...
  10. Montorsi P, De Bernadi F, Muratori M, Cavoretto D, Pepi M. Role of cine-fluoroscopy, transthoracic, and transesophageal echocardiography in patients with suspected prosthetic heart valve thrombosis. Am J Cardiol 2000; 85: 58-64. Go to original source... Go to PubMed...
  11. Barbetseas J, Nagueh SF, Pitsavos Ch, Toutouzas PK, Quinones MA, Zoghbi W. Differentiating thrombus from pannus formation in obstructed mechanical prosthetic valves: An evaluation of clinical, transthoracic and transesophageal echocardiographic parameters. J Am Col Cardiol 1998; 32: 1410-1417. Go to original source...
  12. Lengyel M, Fuster V, Keltai M, et al. Guidelines for management of left-sided prosthetic valve thrombosis: a role for thrombolytic therapy. Consensus Conference on Prosthetic Valve Thrombosis. J Am Coll Cardiol 1997; 30: 1521-1526. Go to original source... Go to PubMed...
  13. Varvařovský I, Harrerová L, Brtko M, Rozsíval V, Dominik J, Procházka E. Trombóza mechanické protézy aortální chlopně léčená trombolytickou léčbou. Cor Vasa 1998; 40: 93-97.
  14. Tong AT, Roudaut R, Ozkan M, et al. Transesophageal echocardiography improves risk assessment of thrombolysis of prosthetic valve thrombosis: results of the international PRO-TEE registry. J Am Coll Cardiol 2004; 43: 77-84. Go to original source... Go to PubMed...
  15. The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology: Guidelines on the management of valvular heart disease. Eur Heart J 2007; 28: 230-268. Go to original source...
  16. Bollag L, Attenhofer Jost ChH, Vogt PR, et al. Symptomatic mechanical heart valve thrombosis: high morbidity and mortality despite successful treatment options. Swiss Med Wkly 2001; 131: 109-116. Go to original source... Go to PubMed...
  17. Rizzoli G, Guglielmi C, Toscano G, et al. Reoperations for acute prosthetic thrombosis and pannus: an assessment of rates, relationship and risk. Eur J Cardiothorac Surg 1999; 16: 74-80. Go to original source... Go to PubMed...
  18. Caceres-Loriga F, Santos-Gracia J. Use of glycoprotein IIb/IIIa receptor antagonist in prosthetic valve thrombosis. Platelets 2010; 21: 583. Go to original source... Go to PubMed...
  19. Aoyagi S, Fukunaga S, Teshima H. Treatment for mechanical valve thrombosis in the right heart: combined pharmacological and mechanical thrombolysis. Artif Organs 2010; 34: 1164. Go to original source... Go to PubMed...
  20. Karthik S, Grayson AD, McCarron EE, Pullan DM, Desmond MJ. Reexploration for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the effect of time delay. Ann Thorac Surg 2004; 78: 527-534. Go to original source... Go to PubMed...
  21. Jayaprakash A, McGrath C, McCullagh E, Smith F, Angelini G, Probert C. Upper gastrointestinal haemorrhage following cardiac surgery: a comparative study with vascular surgery patients from a single centre. Eur J Gastroenterol Hepatol 2004; 16: 191-194. Go to original source... Go to PubMed...
  22. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1671-1681. Go to original source... Go to PubMed...
  23. Turpie AGG, Gunstensen J, Hirsh J, et al. Randomized comparison of two intensities of oral anticoagulant therapy after heart valve replacement. Lancet 1988; 1: 1242-1245. Go to original source... Go to PubMed...
  24. Saour JN, Sieck JO, Mamo LAR, et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428-432. Go to original source... Go to PubMed...
  25. Altman R, Rouvier J, Gurfinkel E, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991; 101: 427-431. Go to original source...
  26. Algra A, Franke CL, Koehler PJJ, et al. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857-865. Go to original source... Go to PubMed...
  27. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Eng J Med 1995; 333: 11-17. Go to original source... Go to PubMed...
  28. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902. Go to original source... Go to PubMed...
  29. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Arial Fibrillation III randomized clinical trial. Lancet 1996; 348: 633-638. Go to original source...
  30. Fihn SD, McDonnel M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multi-centre study. Ann Intern Med 1993; 118: 511-520. Go to original source... Go to PubMed...
  31. Casais P, Luceros AS, Meschengieser S, et al. Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol 2000; 63: 192-196. Go to original source... Go to PubMed...
  32. Beyth RJ, Quinn LM, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized clinical trial. Ann Intern Med 2000; 133: 687-695. Go to original source... Go to PubMed...
  33. Elston-Lafata J, Martin SA, Kaatz S, et al. The cost effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med 2000; 15: 31-37. Go to original source... Go to PubMed...
  34. White RH, McCurdy SA, von Marensdorff H, et al. Home prothrombin time monitoring after the initiation of warfarin therapy: a randomized, prospective study. Ann Intern Med 1989; 111: 730-737. Go to original source... Go to PubMed...
  35. Hasenkam JM, Kimose II, Knudson L, et al. Self-management of oral anticoagulant therapy after heart valve replacement. Eur J Cardiothorac Surg 1997; 11: 935-942. Go to original source... Go to PubMed...
  36. Sawicki PT. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. A structured teaching and selfmanagement program for patients receiving oral anticoagulation: a randomized controlled trial. JAMA 1999; 281: 145-150. Go to original source... Go to PubMed...
  37. Korke H, Korfer R. International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous? Ann Thorac Surg 2001; 72: 44-48. Go to original source... Go to PubMed...
  38. Ansell J, Patel N, Ostrovsky D, et al. Long-term patient selfmanagement of oral anticoagulation. Arch Intern Med 1995; 155: 2185-2189. Go to original source...
  39. Watzke HH, Forberg E, Svolba G, et al. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. Thromb Haemost 2000; 83: 661-665. Go to original source... Go to PubMed...
  40. Cromheecke ME, Levi M, Coly LP, et al. Oral anticoagulation selfmanagement and management by a specialist anticoagulation clinic: a randomized cross-over comparison. Lancet 2000; 356: 97-102. Go to original source... Go to PubMed...
  41. Pengo V, Legnani C, Noventa F, et al, on behalf of the ISCOAT Study Group. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding: a multicenter inception cohort study. Thromb Haemost 2001; 85: 418-422. Go to original source... Go to PubMed...
  42. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception- cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-428. Go to original source... Go to PubMed...
  43. Gitter MJ, Jaeger TM, Petterson TM, et al. Bleeding and thromboembolism during anticoagulant therapy: a population based study in Rochester, Minnesota. Mayo Clin Proc 1995; 70: 725-733. Go to original source... Go to PubMed...
  44. Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 287-310. Go to original source... Go to PubMed...
  45. Dickman LJ, Rettie AE, Kneller MB, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001; 60: 382-387. Go to original source... Go to PubMed...
  46. Kidd RS, Cury TB, Gallagher S, et al. Identification of a null allele of CYP2C9 in an African American exhibiting toxicity of fenytoin. Pharmacogenetics 2001; 11: 803-808. Go to original source... Go to PubMed...
  47. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005; 7: 97-104. Go to original source... Go to PubMed...
  48. Peyvandi F, Spreafico M, Siboni M, et al. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther 2004; 75: 198-203. Go to original source... Go to PubMed...
  49. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-1698. Go to original source... Go to PubMed...
  50. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-649. Go to original source... Go to PubMed...
  51. Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-1751. Go to original source... Go to PubMed...
  52. Oldenburg J, Quenzel EM, Harbrecht U, et al. Missense mutations at ALA-10 in the factor IX propeptidu: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 1997; 98: 240-244. Go to original source... Go to PubMed...
  53. Beyth RJ, Quinn LM, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized clinical trial. Ann Intern Med 2000; 133: 687-695. Go to original source... Go to PubMed...
  54. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99. Go to original source... Go to PubMed...
  55. Landefeld S, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-152. Go to original source... Go to PubMed...
  56. Petitti D, Strom B, Melmon K. Duration of warfarin anticoagulation therapy and the probalities of recurrent thromboembolism and hemorrhage. Am J Med 1986; 81: 255-259. Go to original source... Go to PubMed...
  57. McInnes GT, Helenglass G. The performance of clinics for outpatient control of anticoagulation. J R Coll Physicians Lond 1987; 21: 42-45. Go to PubMed...
  58. Fuller JA, Melb MB. Experiences with long-term anticoagulant treatment. Lancet 1959; 2: 489-491. Go to original source... Go to PubMed...
  59. Mosley DH, Schatz IJ, Breneman GM, et al. Long-term anticoagulant therapy. JAMA 1963; 186: 914-916. Go to original source... Go to PubMed...
  60. Torn M, Algra A, et al. Oral anticoagulation for cerebral ischemia of arterial origin: high initial bleeding risk. Neurology 2001; 57: 1933-1939. Go to original source... Go to PubMed...
  61. Lundstrom R, Ryden L. Hemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis. J Intern Med 1989; 225: 137-142. Go to original source... Go to PubMed...
  62. Forfar JC. A 7-year analysis of hemorrhage in patients in longterm anticoagulant treatment. Br Heart J 1979; 42: 128-132. Go to original source... Go to PubMed...
  63. Janský P. Dabigatran etexilát - přelom v antitrombotické léčbě v kardiologii. Interv Akut Kardiol 2011; 2: 82-86.




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.